Proteolytic Cleavage of Apolipoprotein E in the Down Syndrome Brain

Autor: Ryan J. Day, Elizabeth Head, Troy T. Rohn, Katie McCarty, Kayla E. Ockerse
Rok vydání: 2016
Předmět:
Apolipoprotein E
medicine.medical_specialty
Down syndrome
Pathology
proteolysis
Aging
Intellectual and Developmental Disabilities (IDD)
Neuropathology
Biology
Neurodegenerative
Immunofluorescence
Alzheimer's Disease
Pathology and Forensic Medicine
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Acquired Cognitive Impairment
Genetics
2.1 Biological and endogenous factors
Senile plaques
medicine.diagnostic_test
beta-amyloid
Neurosciences
Colocalization
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Cell Biology
medicine.disease
Brain Disorders
Endocrinology
neurofibrillary tangles
030220 oncology & carcinogenesis
immunohistochemistry
Neurological
Immunohistochemistry
Original Article
paired helical filaments
Dementia
Neurology (clinical)
Geriatrics and Gerontology
Down Syndrome
Chromosome 21
Alzheimer’s disease
030217 neurology & neurosurgery
Zdroj: Aging and disease, vol 7, iss 3
Aging and Disease
Popis: Down syndrome (DS) is one of the most common genetic causes of intellectual disability and is characterized by a number of behavioral as well as cognitive symptoms. Many of the neuropathological features of early-onset Alzheimer’s disease (AD) including senile plaques and neurofibrillary tangles (NFTs) are also present in people with DS as a result of triplication of the amyloid precursor gene on chromosome 21. Evidence suggests that harboring one or both apolipoprotein E4 (APOE4) alleles may increase the risk for AD due to the proteolytic cleavage of apoE4 and a subsequent loss of function. To investigate a role for the apoE proteolysis in vivo, we compared three autopsy groups; 7 DS with AD neuropathology cases over 40 years, 5 young DS cases without AD pathology under 40 years (YDS) and 5 age-matched control cases over 40 years by immunohistochemistry utilizing an antibody that detects the amino-terminal fragment of apoE. Application of this antibody, termed the amino-terminal apoE fragment antibody (nApoECF) revealed labeling of pyramidal neurons in the frontal cortex of YDS cases, whereas in the DS-AD group, labeling with nApoECF was prominent within NFTs. NFT labeling with nApoECF was significantly greater in the hippocampus versus the frontal cortex in the same DS-AD cases, suggesting a regional distribution of truncated apoE. Colocalization immunofluorescence experiments indicated that 52.5% and 53.2% of AT8- and PHF-1-positive NFTs, respectively, also contained nApoECF. Collectively, these data support a role for the proteolytic cleavage of apoE in DS and suggest that apoE fragmentation is closely associated with NFTs.
Databáze: OpenAIRE